ArticleCureus2025
Genitourinary Tuberculosis in a Young Male With Advanced Human Immunodeficiency Virus (HIV) Diagnosed via Urinary Lipoarabinomannan Antigen (TB-LAM): A Case Report From a High-Burden Setting.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genitourinary tuberculosis (GU-TB) is a rare but significant manifestation of extrapulmonary tuberculosis, particularly among immunocompromised individuals. Diagnosis remains difficult in resource-limited settings where access to culture or advanced imaging is restricted. The World Health Organization recently endorsed the urinary lipoarabinomannan (TB-LAM) assay for early tuberculosis detection in people with advanced HIV. We report the case of a 29-year-old mestizo man from Peru with HIV diagnosed in 2018 who had discontinued antiretroviral therapy (ART) shortly after initiation. He reengaged with the Peruvian healthcare system in July 2025, presenting with persistent systemic symptoms, including night sweats, anorexia, and lower abdominal discomfort. Laboratory studies revealed a CD4 count of 237 cells/μL and a viral load of 1.59 million copies/mL. Urinalysis showed sterile pyuria and microscopic hematuria. Chest radiography revealed no pulmonary involvement. Renal ultrasound demonstrated increased parenchymal echogenicity with partial loss of corticomedullary differentiation. Given his immunosuppressed state and nonspecific presentation, a TB-LAM test was performed and returned positive. A diagnosis of GU-TB was established, and the patient was initiated on first-line anti-tuberculosis therapy with concurrent ART reintroduction. He demonstrated a favorable clinical response without immune reconstitution inflammatory syndrome (IRIS). This case highlights the diagnostic utility of TB-LAM in extrapulmonary TB among HIV-positive patients and underscores the need for clinical vigilance in high-burden, low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.